GMTX News and Press, Gemini Therapeutics Inc. From 03/29/21

Gemini Therapeutics (GMTX): FY net loss of $40.8M compared to $41.4M last year.Cash position of approximately $200M.Press Release For further details see: Gemini Therapeutics reports FY results

- Business combination with FS Development Corp. resulted in new public listing, strengthened management team, and cash position of approximately $200 million - Significantly advanced GEM103 clinical development; completed Phase 2a “ReGAtta” study enrollment; ini...

Gemini Therapeutics is bringing precision medicine and genomics to Dry AMD, a disease without an FDA-approved medicine. By focusing on CFH variants of Dry AMD, which represent over 6M patients in the US, the company is the first to bring a recombinant CFH into the clinic. Gemini's...

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Thera...

– Top Line Data for Phase 2a Study Expected in 1H 2021 – Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular diso...

Gemini Therapeutics, Inc., (Nasdaq: GMTX) a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD), today announced that Brian Piekos has been appointed to serve as Chief Financial Officer. Mr. Piekos bri...